Microtubule Inhibitors Induce Cross‐Resistance to Osimertinib Through CaMKII Activation in EGFR ‐Mutated NSCLC
Open Access
- 29 November 2025
- journal article
- Published by Wiley in Cancer Science
- Vol. 117 (2) , 418-428
Abstract
The current standard postoperative adjuvant therapy for patients with epidermal growth factor receptor (EGFR)‐mutated non‐small cell lung cancer (NSCLC) includes chemotherapy, including microtubule inhibitors prior to the administration of osimertinib, an EGFR‐tyrosine kinase inhibitor (TKI). However, multidrug resistance following treatment with microtubule inhibitors has been reported, and the optimal sequence of drug administration for EGFR‐mutated NSCLC remains undefined. In this study, we investigated whether prior treatment with microtubule inhibitors induces acquired cross‐resistance to osimertinib in EGFR‐mutated NSCLC cells in vitro. To model acquired resistance, PC‐9 cells were exposed to vinorelbine or paclitaxel for 18 weeks—approximating the clinical duration of four adjuvant chemotherapy cycles—and subsequent drug sensitivity and signaling pathway alterations were assessed using cell viability assays, RNA sequencing, and immunoblotting. We found that two human NSCLC cell lines derived from PC‐9 exhibited reduced sensitivity to osimertinib after 18 weeks of in vitro treatment with tubulin inhibitors: vinorelbine (PC‐9/VNR) and paclitaxel (PC‐9/PTX). Furthermore, PC‐9/VNR and PC‐9/PTX cells showed activation of FZD7 and calcium/calmodulin‐dependent protein kinase II (CaMKII), along with increased sensitivity to the CaMKII inhibitor KN‐93, which exerted additive or synergistic effects. These findings suggest that CaMKII plays a critical role in EGFR‐TKI resistance. This study underscores the importance of optimizing the timing of EGFR‐TKI administration in the therapeutic sequence for EGFR‐mutated NSCLC.Keywords
This publication has 45 references indexed in Scilit:
- Studying CaMKII: Tools and standardsCell Reports, 2024
- QT-Interval Prolongation, Torsades de Pointes, and Heart Failure With EGFR Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer: Systematic ReviewClinical Lung Cancer, 2024
- Cdc42-driven endosomal cholesterol transport promotes collateral resistance in HER2-positive gastric cancerCancer Letters, 2024
- Canonical and noncanonical Wnt signaling: Multilayered mediators, signaling mechanisms and major signaling crosstalkGenes & Diseases, 2024
- Overcoming Cancer Multi-drug Resistance (MDR): Reasons, mechanisms, nanotherapeutic solutions, and challengesBiomedicine & Pharmacotherapy, 2023
- WNT5A in tumor development and progression: A comprehensive reviewBiomedicine & Pharmacotherapy, 2022
- Inhibition of DCLK1 sensitizes resistant lung adenocarcinomas to EGFR-TKI through suppression of Wnt/β-Catenin activity and cancer stemnessCancer Letters, 2022
- Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLCJournal of Thoracic Oncology, 2021
- Cancer statistics for the year 2020: An overviewInternational Journal of Cancer, 2021
- The synergistic role of ATP‐dependent drug efflux pump and focal adhesion signaling pathways in vinorelbine resistance in lung cancerCancer Medicine, 2018